R & D

Cell>Point has entered into long-term commitments to financially sponsor and support continuing research and development at M. D. Anderson Cancer Center for the EC Technology, In-Situ Hydrogel, N₄ Technology, and Dual Agent Technology platforms. Such research and development work is concentrated in the areas of receptor targeting, tissue hypoxia targeting, transcriptional targeting, tumor apoptosis targeting, gene expression targeting, enzymatic targeting, internal radiotherapy and local regional radio/chemotherapy. While development work has proceeded on all five technology platforms, the company’s principal focus has been on the development of the EC Technology platform compounds. The company believes that the versatility and stability of EC Technology will provide significant opportunities to create new imaging and therapeutic radiopharmaceuticals. Below is the history of EC-G product development.

Beta Cell Technology is being developed to specifically target the function of beta cells in the pancreas. The first indication for use is in the evaluation of the therapeutic efficacy of diabetic drugs in terms of how pancreatic beta cells are affected by and respond to such drugs. In-Situ Hydrogel will provide a high-yield therapeutic delivery system that will be capable of the in-situ treatment of inoperable and unresectable tumors. N4 Technology is a very stable lipophilic technology that is being used to develop new therapeutic approaches for Alzheimer's, Parkinson's, Huntington's disease, and neuroendocrine tumors. The technology is also being used to develop new diagnostic imaging agents for use with PET cameras. Dual Agent Technology is facilitating the development of different combination agents for use with the new dual modality cameras such as SPECT/CT, SPECT/MRI and PET/CT, PET/MRI. One of the attributes of Dual Agent Technology will be the ability to develop targeted combination radio/chemotherapy agents.